Log in

NASDAQ:DRNADicerna Pharmaceuticals News Headlines

$24.89
-0.50 (-1.97 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$24.82
Now: $24.89
$25.79
50-Day Range
$19.56
MA: $22.92
$26.62
52-Week Range
$11.75
Now: $24.89
$27.68
Volume310,900 shs
Average Volume817,772 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.82

Headlines

Dicerna Pharmaceuticals (NASDAQ DRNA) News Headlines

Source:
DateHeadline
Short Interest in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Declines By 7.8%Short Interest in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Declines By 7.8%
www.americanbankingnews.com - July 9 at 3:09 AM
Insider Selling: Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Insider Sells 8,185 Shares of StockInsider Selling: Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Insider Sells 8,185 Shares of Stock
www.americanbankingnews.com - July 7 at 4:14 AM
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) COO James B. Weissman Sells 4,360 SharesDicerna Pharmaceuticals Inc (NASDAQ:DRNA) COO James B. Weissman Sells 4,360 Shares
www.marketbeat.com - July 7 at 4:14 AM
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Expected to Announce Quarterly Sales of $76.04 MillionDicerna Pharmaceuticals Inc (NASDAQ:DRNA) Expected to Announce Quarterly Sales of $76.04 Million
www.americanbankingnews.com - July 5 at 3:56 AM
 Analysts Anticipate Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Will Post Earnings of $0.21 Per Share Analysts Anticipate Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Will Post Earnings of $0.21 Per Share
www.americanbankingnews.com - July 3 at 3:40 PM
Dicerna Pharmaceuticals (NASDAQ:DRNA) Stock Rating Lowered by ValuEngineDicerna Pharmaceuticals (NASDAQ:DRNA) Stock Rating Lowered by ValuEngine
www.marketbeat.com - July 2 at 1:40 AM
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Given Average Rating of "Buy" by BrokeragesDicerna Pharmaceuticals Inc (NASDAQ:DRNA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 30 at 2:04 PM
Bob D. Brown Sells 9,670 Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) StockBob D. Brown Sells 9,670 Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Stock
www.marketbeat.com - June 23 at 8:42 PM
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Short Interest UpdateDicerna Pharmaceuticals Inc (NASDAQ:DRNA) Short Interest Update
www.americanbankingnews.com - June 22 at 1:51 AM
Dicerna nabs Rare Pediatric Disease tag for nedosiran for primary hyperoxaluriaDicerna nabs Rare Pediatric Disease tag for nedosiran for primary hyperoxaluria
seekingalpha.com - June 18 at 1:05 PM
Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary HyperoxaluriaDicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria
finance.yahoo.com - June 18 at 8:05 AM
Dicerna Pharmaceuticals (NASDAQ:DRNA) Receives Buy Rating from B. RileyDicerna Pharmaceuticals (NASDAQ:DRNA) Receives Buy Rating from B. Riley
www.americanbankingnews.com - June 16 at 8:03 AM
Hedge Funds Aren’t Crazy About Dicerna Pharmaceuticals Inc (DRNA) AnymoreHedge Funds Aren’t Crazy About Dicerna Pharmaceuticals Inc (DRNA) Anymore
finance.yahoo.com - June 15 at 12:29 PM
Dicerna to Participate in Jefferies Virtual Global Healthcare ConferenceDicerna to Participate in Jefferies Virtual Global Healthcare Conference
finance.yahoo.com - May 26 at 6:40 PM
DRNA Dicerna Pharmaceuticals, Inc. Common StockDRNA Dicerna Pharmaceuticals, Inc. Common Stock
www.nasdaq.com - May 23 at 11:57 PM
Dicerna Pharmaceuticals (DRNA) Presents At UBS Global Healthcare Conference - SlideshowDicerna Pharmaceuticals (DRNA) Presents At UBS Global Healthcare Conference - Slideshow
seekingalpha.com - May 20 at 5:54 PM
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Analysts Are Way More Bearish Than They Used To BeDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Analysts Are Way More Bearish Than They Used To Be
finance.yahoo.com - May 18 at 8:40 AM
Dicerna to Present at Upcoming May Investor ConferencesDicerna to Present at Upcoming May Investor Conferences
finance.yahoo.com - May 12 at 6:27 PM
Were Hedge Funds Right About Dicerna Pharmaceuticals Inc (DRNA)?Were Hedge Funds Right About Dicerna Pharmaceuticals Inc (DRNA)?
finance.yahoo.com - May 10 at 11:43 PM
Dicerna Pharmaceuticals, Inc. Just Reported A Surprise Loss: Heres What Analysts Think Will Happen NextDicerna Pharmaceuticals, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
finance.yahoo.com - May 10 at 1:42 PM
Dicerna Pharmaceuticals, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen NextDicerna Pharmaceuticals, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
finance.yahoo.com - May 10 at 1:42 PM
Dicerna Pharmaceuticals Inc (DRNA) Q1 2020 Earnings Call TranscriptDicerna Pharmaceuticals Inc (DRNA) Q1 2020 Earnings Call Transcript
finance.yahoo.com - May 9 at 8:42 PM
Edited Transcript of DRNA earnings conference call or presentation 7-May-20 8:30pm GMTEdited Transcript of DRNA earnings conference call or presentation 7-May-20 8:30pm GMT
finance.yahoo.com - May 8 at 8:54 PM
The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For TakedaThe Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda
finance.yahoo.com - May 8 at 3:53 PM
Dicerna Pharmaceuticals (NASDAQ:DRNA) Receives "Buy" Rating from Chardan CapitalDicerna Pharmaceuticals (NASDAQ:DRNA) Receives "Buy" Rating from Chardan Capital
www.marketbeat.com - May 8 at 7:55 AM
Dicerna Pharmaceuticals (DRNA) "Buy" Rating Reiterated at HC WainwrightDicerna Pharmaceuticals' (DRNA) "Buy" Rating Reiterated at HC Wainwright
www.marketbeat.com - May 8 at 7:55 AM
Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Misses Revenue EstimatesDicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 7 at 9:50 PM
Dicerna Pharmaceuticals EPS misses by $0.58, misses on revenueDicerna Pharmaceuticals EPS misses by $0.58, misses on revenue
seekingalpha.com - May 7 at 4:50 PM
Dicerna Announces Appointment of Douglas Pagán as Chief Financial OfficerDicerna Announces Appointment of Douglas Pagán as Chief Financial Officer
finance.yahoo.com - May 7 at 4:50 PM
Dicerna Announces First Quarter 2020 Financial Results and Provides a Business UpdateDicerna Announces First Quarter 2020 Financial Results and Provides a Business Update
finance.yahoo.com - May 7 at 4:50 PM
Dicerna to Report First Quarter 2020 Financial Results on May 7, 2020Dicerna to Report First Quarter 2020 Financial Results on May 7, 2020
finance.yahoo.com - April 30 at 9:57 PM
Were Not Worried About Dicerna Pharmaceuticalss (NASDAQ:DRNA) Cash BurnWe're Not Worried About Dicerna Pharmaceuticals's (NASDAQ:DRNA) Cash Burn
finance.yahoo.com - April 29 at 9:53 AM
We're Not Worried About Dicerna Pharmaceuticals's (NASDAQ:DRNA) Cash BurnWe're Not Worried About Dicerna Pharmaceuticals's (NASDAQ:DRNA) Cash Burn
finance.yahoo.com - April 29 at 9:53 AM
Diving Into Dicerna PharmaceuticalsDiving Into Dicerna Pharmaceuticals
seekingalpha.com - April 14 at 3:32 PM
Biotech vet Gilman's startup earns $190M-plus in Roche dealBiotech vet Gilman's startup earns $190M-plus in Roche deal
finance.yahoo.com - April 8 at 7:26 AM
Dicerna Provides Initial Observations From PHYOX™3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria and an Update on Data Presentation PlanDicerna Provides Initial Observations From PHYOX™3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria and an Update on Data Presentation Plan
finance.yahoo.com - March 31 at 11:21 AM
Dicerna Addresses Business Continuity in Response to COVID-19 PandemicDicerna Addresses Business Continuity in Response to COVID-19 Pandemic
finance.yahoo.com - March 26 at 5:16 PM
Stocks Flashing Renewed Technical Strength: Dicerna PharmaceuticalsStocks Flashing Renewed Technical Strength: Dicerna Pharmaceuticals
finance.yahoo.com - March 23 at 6:52 PM
Dicerna Pharmaceuticals, Inc. Common Stock (DRNA) Insider Activity | NasdaqDicerna Pharmaceuticals, Inc. Common Stock (DRNA) Insider Activity | Nasdaq
www.nasdaq.com - March 21 at 7:36 AM
Dicernas DCR-A1AT an Orphan Drug in U.S. for alpha-1 antitrypsin deficiencyDicerna's DCR-A1AT an Orphan Drug in U.S. for alpha-1 antitrypsin deficiency
seekingalpha.com - March 19 at 1:02 PM
Dicerna Pharmaceuticals (DRNA) Presents At Cowen and Comapny 40th Annual Health Care Conference - SlideshowDicerna Pharmaceuticals (DRNA) Presents At Cowen and Comapny 40th Annual Health Care Conference - Slideshow
seekingalpha.com - March 17 at 8:19 AM
Edited Transcript of DRNA earnings conference call or presentation 27-Feb-20 9:30pm GMTEdited Transcript of DRNA earnings conference call or presentation 27-Feb-20 9:30pm GMT
finance.yahoo.com - March 9 at 5:25 PM
Earnings Beat: Dicerna Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsEarnings Beat: Dicerna Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
finance.yahoo.com - February 29 at 1:10 PM
Dicerna Pharmaceuticals EPS misses by $0.45, misses on revenueDicerna Pharmaceuticals EPS misses by $0.45, misses on revenue
seekingalpha.com - February 27 at 5:58 PM
Dicerna™ Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateDicerna™ Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - February 27 at 5:58 PM
Dicerna™ to Report Fourth Quarter and Full Year 2019 Financial Results on Feb. 27, 2020Dicerna™ to Report Fourth Quarter and Full Year 2019 Financial Results on Feb. 27, 2020
finance.yahoo.com - February 20 at 10:56 PM
Dicerna™ to Present at Upcoming Investor ConferencesDicerna™ to Present at Upcoming Investor Conferences
finance.yahoo.com - February 18 at 5:49 PM
Dicerna™ Appoints Stephen Doberstein, Ph.D., to Board of DirectorsDicerna™ Appoints Stephen Doberstein, Ph.D., to Board of Directors
finance.yahoo.com - February 10 at 8:10 AM
Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - February 3 at 7:09 PM
Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin DeficiencyDicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
finance.yahoo.com - December 17 at 8:19 AM
This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.